Novel Heteroaryl Fluoroalkenes as DGK Inhibitors for Treating Cancer, Particularly Metastatic Melanoma.
Rachel MataPublished in: ACS medicinal chemistry letters (2024)
Provided herein are novel heteroaryl fluoroalkenes as DGK inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, particularly metastatic melanoma, and processes for preparing such compounds.